Paul Edwards Posted June 25, 2015 Share Posted June 25, 2015 Trial stopped - see below Thanks for Chuck Maack for alerting us to this. Galeterone (TOK-001) is a highly selective, multi-targeted, oral small molecule, drug candidate for the treatment of prostate cancer that disrupts androgen receptor (AR) signalling, the key driver of prostate cancer growth, via multiple mechanisms of action: androgen receptor degradation, which reduces the amount of androgen receptor protein in the tumor cells; inhibition of the enzyme CYP17, which blocks the synthesis of testosterone; and androgen receptor antagonism, which blocks the binding of testosterone or DHT (dihydrotestoterone) with the androgen receptor. Tokai Pharmaceuticals, the manufacturer of Galeterone, has started to enroll US patients into a randomized Phase III clinical trial of treatment with Galeterone. Patients will be randomized to treatment with either Galeterone or Enzalutamide. There will be Australian study locations commencing shortly. Click for more information. Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.